Precigen, Inc. (NASDAQ:PGEN – Get Free Report) has received an average recommendation of “Moderate Buy” from the six ratings firms that are covering the company, Marketbeat reports. One equities research analyst has rated the stock with a sell recommendation, one has issued a hold recommendation and four have issued a buy recommendation on the company. The average 12-month price objective among brokerages that have covered the stock in the last year is $13.25.
A number of research analysts have weighed in on PGEN shares. Zacks Research cut shares of Precigen from a “strong-buy” rating to a “hold” rating in a research note on Monday, October 5th. Wall Street Zen upgraded shares of Precigen from a “buy” rating to a “strong-buy” rating in a research note on Sunday, November 8th. Raymond James Financial set a $12.00 price target on shares of Precigen in a report on Thursday, November 5th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Precigen in a report on Thursday, October 15th. Finally, HC Wainwright upped their price objective on Precigen from $14.00 to $18.00 and gave the company a “buy” rating in a research note on Wednesday, August 5th.
Check Out Our Latest Report on Precigen
Insiders Place Their Bets
Hedge Funds Weigh In On Precigen
Several large investors have recently modified their holdings of PGEN. WCG Wealth Advisors LLC purchased a new position in Precigen in the 3rd quarter valued at approximately $209,000. Entropy Technologies LP bought a new position in shares of Precigen in the third quarter worth $500,000. Jump Financial LLC purchased a new position in shares of Precigen in the third quarter valued at $2,511,000. Marshall Wace LLP purchased a new position in shares of Precigen in the third quarter valued at $432,000. Finally, First Trust Advisors LP raised its stake in shares of Precigen by 30.2% during the 3rd quarter. First Trust Advisors LP now owns 2,623,975 shares of the biotechnology company’s stock valued at $22,461,000 after purchasing an additional 609,316 shares during the period. Hedge funds and other institutional investors own 33.51% of the company’s stock.
Precigen Trading Down 5.3%
Shares of Precigen stock opened at $4.30 on Thursday. The firm has a market cap of $1.54 billion, a PE ratio of 43.00 and a beta of 1.01. Precigen has a 1 year low of $3.04 and a 1 year high of $8.98. The company has a debt-to-equity ratio of 1.12, a current ratio of 5.58 and a quick ratio of 4.83. The stock has a fifty day moving average price of $6.68 and a 200-day moving average price of $5.28.
Precigen (NASDAQ:PGEN – Get Free Report) last issued its quarterly earnings results on Wednesday, November 4th. The biotechnology company reported $0.08 earnings per share for the quarter, topping analysts’ consensus estimates of $0.06 by $0.02. The company had revenue of $74.15 million for the quarter, compared to the consensus estimate of $71.55 million. Precigen had a net margin of 15.55% and a return on equity of 57.93%. The firm’s quarterly revenue was up 2437.6% on a year-over-year basis. During the same period in the previous year, the firm earned ($1.06) EPS. Equities research analysts anticipate that Precigen will post 0.23 EPS for the current year.
Precigen Company Profile
Precigen, Inc. is a biotechnology company focused on developing gene and cell therapies, including engineered immunotherapies. The company is based in Germantown, Maryland, and its roots include Intrexon, which adopted the Precigen name in 2020. Its approved product, PAPZIMEOS (zopapogene imadenovec-drba), is a gene therapy for adults with recurrent respiratory papillomatosis, a rare condition associated with human papillomavirus types 6 and 11. Precigen is also developing investigational therapies for cancers and other diseases.
See Also
- Five stocks we like better than Precigen
- Ondas Is Building a Defense Growth Engine, But Can It Deliver on Its Backlog?
- Orbiting Growth: Federal Contracts Boost Viasat’s Outlook
- Modine Manufacturing Scales Up to Solve the AI Heat Problem
- Nebius Revenue Is Surging, But Its Spending Is Raising Bigger Questions
Receive News & Ratings for Precigen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Precigen and related companies with MarketBeat.com's FREE daily email newsletter.
